Hugel posts record first-half net sales exceeding KRW200 billion in H1 2025

The net sales and operating profit for Q2 hit KRW110.3 billion and KRW56.7 billion, up 15.5% and 33.6% on-year, respectively The sales overseas, led by launch of the toxin in the US and expanded shipments to China this year, drive strong outcome Net sales in cosmetics, the new growth engine, show a 104.5% increase on-year […]

Ubitium and ADTechnology Collaborate to Bring Universal Processor to Market

Ubitium and ADTechnology Collaborate to Bring Universal Processor to Market GlobeNewswire August 06, 2025 Düsseldorf, Aug. 06, 2025 (GLOBE NEWSWIRE) — ADTechnology, Korea's largest semiconductor design house, has entered a development partnership with Ubitium, a German fabless semiconductor innovator, to bring its revolutionary UB410 microprocessor to silicon. The UB410 is a next-generation general-purpose microprocessor that

Caledonia Mining Corporation Plc Notification of relevant change to significant shareholder

Caledonia Mining Corporation Plc Notification of relevant change to significant shareholder GlobeNewswire August 06, 2025 ST HELIER, Jersey, Aug. 06, 2025 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) announces that it received notification on August 4, 2025 from BlackRock, Inc. that on August 1,

ZPMC Hosts “Transportation and Smart Port Construction” Media Open Day to Showcase China’s Vision for Future Port Innovation

ZPMC Hosts “Transportation and Smart Port Construction” Media Open Day to Showcase China's Vision for Future Port Innovation GlobeNewswire August 06, 2025 SHANGHAI, Aug. 06, 2025 (GLOBE NEWSWIRE) — On July 25, Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC) held the “Transportation and Smart Port Construction” media open day in Changxing, Shanghai, under the theme:

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30%

New anti-colic system delivers clinically tested relief for newborn digestive discomfort Thyseed, an established name in global infant care, has announced the launch of its newborn baby bottle featuring proprietary bottom vent technology for global markets. Clinical trials confirm that this design reduces colic and spit-up by more than 30% among infants aged 0-3 months.

Flex LNG – Invitation to the 2025 Second Quarter Presentation

Flex LNG Ltd (“Flex LNG” or the “Company”) will release its unaudited financial results for the second quarter of 2025 on Wednesday August 20, 2025, on or about 07:00 CEST (1:00 a.m. EST). In connection with the earnings release, a live video webcast will be held at 15:00 CEST (9:00 a.m. EST) on the same

Thyseed Is Set to Support Southeast Asian Families with Safer Infant Feeding Solutions, Powered by Medical-Grade Technology

Thyseed, an established name in global infant care, recently announced plans to introduce its premium, safety-certified feeding solutions to Southeast Asian households in 2025. With an established presence in the United States, Russia, and mainland China, Thyseed is committed to extending its industry-leading safety standards to new markets. Since its inception, Thyseed has championed a

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors

(Brussels:ONWD),(Euronext Amsterdam:ONWD),(OTC US:ONWRY),(Other OTC:ONWRY), Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

(Brussels:GLPG),(Euronext Amsterdam:GLPG), Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma GlobeNewswire August 06, 2025 Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration

Scroll to Top